Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage form

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 8, 2005, Pages 321-334

  Agrawal, Shrutidevi ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

BCS; Bioavailability; Fixed dose combination; Permeability; Rifampicin; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DECOMPOSITION; DRUG DOSAGE FORM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG SOLUBILITY; IN VIVO STUDY; JEJUNUM; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; SINGLE DRUG DOSE; STOMACH PH;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 28044443143     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.464     Document Type: Article

References (55)

1. WHO Report 2003. Global Tuberculosis Control. Surveillance, Planning, Financing. WHO/CDS/TB/2003.316. World Health Organization: Geneva.
2. WHO Report 2002. Global Tuberculosis Control. Surveillance, Planning, Financing. WHO/CDS/TB/2002.295. World Health Organization: Geneva.
3. Blomberg B, Evans P, Phanouvong S, Nunn P. Informal Consultation on 4-drug Fixed Dose Combinations (4FDCs) Compliant with the WHO Model List of Essential Drugs. 15-17 August 2001. WHO/CDS/TB/2002.299. World Health Organization: Geneva.
4. Laing R, Fourie B, Ellard G, et al. Fixed-dose Combination Tablets for the Treatment of Tuberculosis. Report of an Informal Meeting held in Geneva Tuesday, 27 April 1999, WHO/CDS/CPC/TB/99.267. World Health Organization: Geneva.
5. McIlleron H, Wash P, Burger A, Folb P, Smith P. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6: 356-361.
6. Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2002; 233: 169-177.
7. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations at the same dose levels. Int J Clin Pharmacol Ther 2002; 40: 474-481.
8. Panchagnula R, Kaur KJ, Singh I, Kaul CL. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Int J Tuberc Lung Dis 1999; 3: S336-S342.
9. Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, et al. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsule. Int J Tuberc Lung Dis 1998; 2: 824-830.
10. Nyazema NZ, Rabvukwa P, Gumbo J, Ndudzo P, Chitemerere C. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid: a case for a fixed dose combination (FDC) for the treatment of tuberculosis. Cent Afr J Med 1999; 45: 141-144.
11. Padgoankar KA, Revankar SN, Bhatt AD, et al. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. Int J Tuberc Lung Dis 1999; 3: 627-631.
12. Pillai G, Fourie P, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3: S309-S316.
13. Dressman JB, Amidon GL, Christos Reppas, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-20.
14. Cavenaghi R. Rifampicin raw material characteristics and their effect on bioavailability. Bull Int Union Tuberc Lung Dis 1989; 64: 36-37.
15. Pelizza G, Nebuloni M, Ferrari P, Gallo GG. Polymorphism of rifampicin. II Farmaco 1977; 32: 471-481.
16. Boman G, Lundgren P, Stjernstrom G. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: Adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 1975; 8: 293-299.
17. Buniva G, Pagani V, Carozzi A. Bioavailability of rifampicin capsules. Int J Clin Pharmacol 1983; 21: 404-409.
18. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001; 228: 53-67.
19. Singh S, Mariappan TT, Sankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from antitubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001; 228: 5-17.
20. Acocella G. Human bioavailability studies. IUATLD Symposium 'Quality control of anti-tuberculosis drugs', Dubrovnik, 6 October 1988. Bull Int Union Tuberc Lung Dis 1989; 64: 38-40.
21. Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis 1999; 3: S301-S308.
22. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
23. Lobenberg R, Amidon GL. Modern bioavailability and biopharmaceutics, classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000; 50: 3-12.
24. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002; 42: 620-643.
25. Avdeef A. High throughput measurements of solubility profiles. In Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies, Testa B, Waterbeemd H, Folkers G, Guy R (eds). Wiley-VCH: Weinheim, 2001a; 305-325.
26. EPA. United States Environmental Protection Agency. Prevention, Pesticides and Toxic Substances (7101): Product Properties Test Guidelines OPPTS 830.7550. Partition Coefficient (n-octanol/water). Shake Flask Method. EPA 712-C-96-038. August 1996.
27. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996; 13: 1136-1142.
28. FDA. United States Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. August 2000.
29. Sharma P. Role of Absorption Enhancers in Increasing Peroral Bioavailability of Drugs: Absorption Enhancement, Mechanistic and Toxicity Studies. PhD thesis. National Institute of Pharmaceutical Education and Research, 2002.
30. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001; 39: 209-228.
31. Panchagnula R, Sood A, Sharda N, Kaur KJ, Kaul CL. Analysis of rifampicin and its main metabolite in presence of pyrazinamide and isoniazid in plasma and urine samples by HPLC method. J Pharm Biomed Anal 1999; 18: 1013-1020.
32. Agrawal S, Panchagnula. R. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms. Pharmazie 2004; 59: 775-781.
33. Ritschel WA, Kearns GL. Handbook of Basic Pharmacokinetics Including Clinical Applications. 5th edn. American Pharmaceutical Association: Washington, 1999; 242-269, 296-303.
34. Sutton SC, Rinaldi MTS, Vukovinsky KE. Comparison of the gravimetric, phenol red, and 14C-PEG 3350 methods to determine water absorption in the rat single pass intestinal perfusion model. AAPS Pharm Sci 2001; 3: 1-5.
35. Sutton SC, Rinaldi MTS, McCarthy JM, Vukovnisky KE. A statistical method for the determination of absorption rate constant estimated using the rat single pass intestinal perfusion model and multiple linear regression. J Pharm Sci 2002; 91: 1046-1053.
36. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Sci Tech Today 1998; 1: 387-393.
37. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Topics Med Chem 2001; 1: 277-351.
38. Binda G, Domenichini E, Gottardi A. Rifampicin a general review. Arzneinmittelforschung 1971; 21: 1908-1977.
39. Zhang JN, Liu XG, Zhu M, Chiu FCK, Li RC. Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 1998; 10: 354-359.
40. Accocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-127.
41. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Influence of enzyme induction by rifampicin on its presystemic metabolism. Pharmacol Ther 1987; 33: 201-204.
42. Acocella G, Conti R, Luisetti M, Pozzi E, Grassi C. Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short course regimens: Single administration study. Am Rev Respir Dis 1985; 132: 510-515.
43. Panchagnula R, Thomas NS. Pharmacokinetics and biopharmaceutics in drug development. Int J Pharm 2000; 201: 131-150.
44. Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001; 44: 1313-1333.
45. Lipka E, Amidon GL. Setting bioequivalence requirements for drug development based on preclinical data: optimising oral drug delivery systems. J Control Rel 1999; 62: 41-49.
46. Langguth P, Merkle HP, Amidon GL. Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm Res 1994; 11: 528-535.
47. Fagerholm U, Lindahl A, Lennernas H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol 1997; 49: 687-690.
48. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutic classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921-925.
49. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampicin. Drug Metab Rev 1981; 12: 159-218.
50. Leveille-Webster CR, Arias IM. The biology of the P-glycoproteins. J Membr Biol 1995; 143: 89-102.
51. Tolle-Sander S, Jarkko R, Wring S, Polli JW, Polli JE. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 2003; 20: 757-764.
52. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931-959.
53. Eytan GD, Regev R, Oren G, Hurwitz CD, Assaraf YG. Efficiency of P-glycoprotein mediated exclusion of rhodamine dyes from multi-drug resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 1997; 248: 104-112.
54. Yew WN. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Safety 2002; 25: 111-133.
55. Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97-112.